# Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

> **NCT02860286** · PHASE2 · COMPLETED · sponsor: **Epizyme, Inc.** · enrollment: 74 (actual)

## Conditions studied

- Mesothelioma
- BAP1 Loss of Function

## Interventions

- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT02860286
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2018-06
- **Final completion:** 2019-05
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2021-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02860286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02860286, "Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02860286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*